Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2013, Vol. 35 ›› Issue (1): 64-68.doi: 10.3881/j.issn.1000-503X.2013.01.012

• Original Articles • Previous Articles     Next Articles

Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAFV600E Mutationand Rearranged during Transfection Proto-oncogene Protein Expression

MENG Chao1, GAO Jie2, LIANG Jun1, LIANG Zhi-yong2, LIN Yan-song3   

  1. 1Department of Oncology, the Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China2Department of Pathology, 3Department of Nuclear Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China
  • Received:2012-04-25 Online:2013-03-07 Published:2013-03-07
  • Supported by:
    Supported by the National Natural Sciences Foundation of China (30970850)and the Research Special Fund of the Health Industry(201202012);第一、二位作者对本文贡献一致The first two authors contributed equally to this article

Abstract: Objective To investigate the aggressive properties of papillary thyroid cancer (PTC) with concurrent BRAFV600Emutation and rearranged during transfection (RET) proto-oncogene protein expression. Methods Fifty pathologically confirmed PTC patients who had received thyroidectomy were enrolled in this study. BRAFV600E mutation was detected by real time polymerase chain reaction (RT-PCR), while RET protein expression was measured by immunohistochemical SP method. Clinical and pathological features were compared between the concurrent BRAFV600E mutation and RET protein expression group (n=24) and BRAFV600E mutation or RET protein expression alone group (n=19). Seven patients were ruled out from the final analysis due to the absence of either BRAFV600E mutation or RET protein expression. Results Of these 50 patients, BRAFV600E mutation and RET protein expression were detected in 38 patients (76%) and 28 patients (56%), respectively. Concurrent BRAFV600E mutation and RET expression was detected in 24 patients (48%). Compared with the concurrent BRAFV600E mutation and RET protein expression group, the BRAFV600E mutation or RET protein expression alone group had relatively poorer tissue differentiation and higher prognostic score (P=0.011, P=0.022). Conclusion PTC patients with concurrent BRAFV600E mutation and RET expression present poorer differentiation, more highly aggressive variant in carcinoma tissues, and higher cancer-related mortality risk.

Key words: BRAFV600E mutation, tyrosine kinase receptor protein expression, papillary thyroid cancer, aggressiveness

CLC Number: